Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the...

Related Keywords

United States ,Chicago ,Illinois ,American ,Talquetamab Monotherapy ,Satu Glawe ,Bhagirathbhai Dholaria ,Christie Corbett ,Chris Heuck ,Myeloma Center ,Companies Of Johnson ,Exchange Commission ,Janssen Research Development ,Oncology At Vanderbilt University Medical Center ,Receptor Familyc Group ,None Of The Janssen Pharmaceutical Companies ,Division Of Hematology ,European Commission ,Johnson ,Janssen Biotech Inc ,National Comprehensive Cancer Network ,American Society Of Clinical Oncology ,American Society Of Hematology ,University Of Arkansas ,Janssen Pharmaceutical Companies Of Johnson ,Eastern Cooperative Oncology Group ,Janssen Pharmaceutical Companies ,Clinical Oncology ,Carolina Schinke ,Associate Professor ,Medical Sciences ,Humoral Immunity ,Refractory Multiple Myeloma Treated ,Evaluating Talquetamab ,Assistant Professor ,Vanderbilt University Medical Center ,Global Medical Head ,Janssen Research ,Part One ,Orphan Drug Designation ,Breakthrough Therapy Designation ,Biologics License Application ,Janssen Biotech ,National Comprehensive Cancer ,Interference With Serological ,With Determination ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Janssen Pharmaceutical ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Refractory Multiple ,Patients With ,Refractory Multiple Myeloma ,Oral Presentation ,American Society ,Natl Acad Sci United ,Prescribing Information ,Janssen Oncology ,